GUMDROP : A Phase 2 Randomized Study of Dalantercept in Combination With Axitinib Compared to Axitinib Alone as Second Line Treatment in Patients With Metastatic Renal Cell Carcinoma

Created by Nancy Dawson, last modified on Jan 15, 2013

Description:

The purpose of Part 1 of this study is to evaluate the safety and tolerability of dalantercept in combination with axitinib as second line treatment in patients with metastatic renal cell carcinoma (RCC) to determine the recommended dose level of dalantercept in combination with axitinib for Part 2.
The purpose of Part 2 of this study is to determine whether treatment with dalantercept in combination with axitinib prolongs progression free survival (PFS) compared to axitinib alone as second line treatment in patients with metastatic renal cell carcinoma (RCC).

Link:

Link to study in ClinicalTrials.gov

Site:

Georgetown University Hospital

Principal Investigator:

Dr. Michael Atkins